Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections

Journal of Infection

Volumn 49, Issue 2, 2004, Pages 115-125

  Low, Donald E ^a   Felmingham, David ^b   Brown, Steve D ^c   Rangaraju, Manickam ^d   Nusrat, Roomi ^d  

^a UNIVERSITY OF TORONTO   (Canada)

^b GR Micro Ltd   (United Kingdom)

^c CMI   (United States)

^d SANOFI   (France)

Author keywords

Acute exacerbations of bronchitis; Acute maxillary sinusitis; Community acquired pneumonia; Telithromycin

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFUROXIME AXETIL; CLARITHROMYCIN; ERYTHROMYCIN; PENICILLIN G; TELITHROMYCIN; TROVAFLOXACIN;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNICABLE DISEASE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MAXILLA SINUSITIS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; PENICILLIN RESISTANCE; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; RESPIRATORY TRACT INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; BACTERIA; BRONCHITIS; CHRONIC DISEASE; CLINICAL TRIALS, PHASE III; CLINICAL TRIALS, PHASE IV; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; KETOLIDES; MACROLIDES; MALE; MICROBIAL SENSITIVITY TESTS; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS; SINUSITIS;

EID: 3242805224     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2004.03.009     Document Type: Article

References (52)

1. Armstrong G.L. Pinner R.W. Outpatient visits for infectious diseases in the United States, 1980 through 1996 Arch Intern Med 159 1999 2531-2536
2. Fine M.J. Smith M.A. Carson C.A. et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis JAMA 275 1996 134-141
3. Minogue M.F. Coley C.M. Fine M.J. Marrie T.J. Kapoor W.N. Singer D.E. Patients hospitalized after initial outpatient treatment for community-acquired pneumonia Ann Emerg Med 31 1998 376-380
4. Niederman M.S. McCombs J.S. Unger A.N. Kumar A. Popovian R. The cost of treating community-acquired pneumonia Clin Ther 20 1998 820-837
5. Niederman M.S. McCombs J.S. Unger A.N. Kumar A. Popovian R. Treatment cost of acute exacerbations of chronic bronchitis Clin Ther 21 1999 576-591
6. McGuire A. Irwin D.E. Fenn P. et al. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales Value Health 4 2001 370-375
7. Niederman M.S. Mandell L.A. Anzueto A.A. et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention Am J Respir Crit Care Med 163 2001 1730-1754
8. Ball P. Make B. Acute exacerbations of bronchitis. An international comparison Chest 113 1998 199S-204S
9. Bishai W.R. Issues in the management of bacterial sinusitis Otolaryngol Head Neck Surg 127 Suppl. 6 2002 S3-S9
10. Pfaller M.A. Ehrhardt A.F. Jones R.N. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment Am J Med 111 Suppl 9A 2001 4S-12S
11. Sokol W. Epidemiology of sinusitis in the primary care setting: results from the 1999-2000 respiratory surveillance program Am J Med 111 Suppl. 9A 2001 19S-24S
12. Fang G.D. Fine M. Orloff J. et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases Medicine (Baltimore) 69 1990 307-316
13. Marrie T.J. Community-acquired pneumonia: epidemiology, etiology, treatment Infect Dis Clin N Am 12 1998 723-740
14. Hammerschlag M.R. Community-acquired pneumonia due to atypical organisms in adults: diagnosis and treatment Infect Dis Clin Pract 8 1999 232-240
15. Linder J.A. Stafford R.S. Antibiotic treatment of adults with sore throat by community primary care physicians. A national survey, 1989-1999 JAMA 286 2001 1181-1186
16. American Thoracic Society Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention Am J Respir Crit Care Med 163 2001 1730-1754
17. Brooks I. Gooch W.M. III Jenkins S.G. Medical management of acute bacterial sinusitis. Recommendations of a clinical advisory committee on pediatric and adult sinusitis Ann Otol Rhinol Laryngol 182 2000 2-20
18. ERS Task Force Report Guidelines for management of adult community-acquired lower respiratory tract infections Eur Respir J 11 1998 986-991
19. Hoban D.J. Doern G.V. Fluit A.C. Roussel-Delvallez M. Jones R.N. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999 Clin Infect Dis 32 Suppl. 2 2001 S81-S93
20. Hoban D. Waites K. Felmingham D. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance study Diagn Microbiol Infect Dis 45 2003 251-259
21. Felmingham D. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study J Infect 44 Suppl. A 2002 3-10
22. Katz K.C. McGeer A.J. Duncan C.L. et al. Emergence of macrolide resistance in throat culture isolates of group A streptococci in Ontario, Canada, in 2001 Antimicrob Agents Chemother 47 2003 2370-2372
23. Barry A.L. Fuchs P.C. Brown S.D. In vitro activities of the ketolide HMR 3647 against recent Gram-positive clinical isolates and Haemophilus influenzae Antimicrob Agents Chemother 42 1998 2138-2140
24. Pankuch G.A. Hoellman D.B. Lin G. Bajakosouzian S. Jacobs M.R. Appelbaum P.C. Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and Moraxella catarrhalis by MIC determination and time-kill assay Antimicrob Agents Chemother 42 1998 3032-3034
25. Roblin P.M. Hammerschlag M.R. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae Antimicrob Agents Chemother 42 1998 1515-1516
26. Schülin T. Wennersten C.B. Ferraro M.J. Moellering R.C. Eliopoulous G.M. Susceptibilities of Legionella spp. to newer antimicrobials in vitro Antimicrob Agents Chemother 42 1998 1520-1523
27. Davies T.A. Dewasse B.E. Jacobs M.R. Appelbaum P.C. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae Antimicrob Agents Chemother 44 2000 414-417
28. Khair O.A. Andrews J.M. Honeybourne D. Jevons G. Vacheron F. Wise R. Lung concentrations of telithromycin after oral dosing J Antimicrob Chemother 47 2001 837-840
29. Muller-Serieys C. Soler P. Cantalloube C. et al. Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647) Antimicrob Agents Chemother 45 2001 3104-3108
30. Hagberg L. Torres A. van Rensburg D. Leroy B. Rangaraju M. Ruuth E. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia Infection 30 2002 378-386
31. Dunbar L.M. Hassman J. Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults Clin Ther 26 2004 48-62
32. Pullman J. Champlin J. Vrooman P.S. Efficacy and tolerability of once daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults Int J Clin Pract 57 2003 377-384
33. Carbon C. Moola S. Velancsics I. Leroy B. Rangaraju M. Decosta P. Efficacy of telithromycin, a new once-daily ketolide antimicrobial, in the treatment of community-acquired pneumonia Clin Microbiol Infect 9 2003 691-703
34. van Rensburg D.J. Matthews P.A. Leroy B. Efficacy and safety of telithromycin in community-acquired pneumonia Curr Opin Med Res 18 2002 397-400
35. Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Fogarty C. Patel T.C. Galbraith H. Zuberbuhler G.A. Leroy B. Efficacy of the first ketolide antibacterial, telithromycin, in the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae 2001 American Society for Microbiology Washington DC
36. Abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague Fogarty C. van Rensburg D. De Salvo C. Rangaraju M. Nusrat R. Efficacy of a 7-day course of oral telithromycin 800 mg once daily in community-acquired pneumonia caused by resistant Streptococcus pneumoniae 2004
37. Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy Tellier G. Isakov T. Peterman W. Patel M. Lavin B. Efficacy and safety of telithromycin (800 mg once daily) for 5 or 7 days vs. clarithromycin (500 mg twice daily) for 10 days in the treatment of patients with community-acquired pneumonia 2002 American Society for Microbiology Washington, DC
38. Aubier M. Aldons P.M. Leak A. et al. Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis Respir Med 96 2002 862-887
39. Zervos M.J. Heyder A.M. Leroy B. Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis J Int Med Res 31 2003 157-169
40. Abstracts of the 13th Meeting of the European Respiratory Society, Vienna Fogarty C. de Wet R. Nusrat R. Five-day telithromycin is as effective as 10 day clarithromycin in the treatment of acute exacerbations of chronic bronchitis 2003
41. Roos K. Brunswig-Pitschner C. Kostrica R. et al. Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis Chemotherapy 48 2002 100-108
42. Luterman A. Tellier G. Lasko B. Leroy B. Efficacy and tolerability of the ketolide telithromycin (HMR 3647) for 5 or 10 days vs. amoxicillin/clavulanic acid for 10 days in the treatment of acute maxillary sinusitis (AMS) in adults Ear Nose Throat 82 2003 576-590
43. Buchanan P. Stephens T. Leroy B. Telithromycin vs. cefuroxime axetil in acute maxillary sinusitis Am J Rhinol 17 2003 369-377
44. National Committee for Clinical Laboratory Standards (NCCLS). Document M100S11. Wayne, PA: NCCLS; 2001.
45. Sutcliffe J. Grebe T. Tait-Kamradt A. Wondrack L. Detection of erythromycin-resistant determinants by PCR Antimicrob Agents Chemother 40 1996 2562-2566
46. Farrell D.J. Morrissey I. Bakker S. Felmingham D. Molecular characterization of macrolide mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT study 1999-2000 J Antimicrob Chemother 50 Suppl. S1 2002 39-47
47. Fogarty C. Kohno S. Buchanan P. Aubier M. Baz M. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin J Antimicrob Chemother 51 2003 947-955
48. Bonnefoy A. Guitton M. Delachaume C. Le Priol P. Girard A.-M. In vivo efficacy of the new ketolide telithromycin (HMR 3647) in murine infection models Antimicrob Agents Chemother 45 2001 1688-1692
49. Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Drusano G.L. Preston S.L. Decosta P. Rangaraju M. Leroy B. Pharmacokinetics (PK) and pharmacodynamics (PD) of telithromycin in the treatment of community-acquired pneumonia (CAP) 2001 American Society for Microbiology Washington, DC
50. Namour F. Wessels D.H. Pascual M.H. Reynolds D. Sultan E. Lenfant B. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses Antimicrob Agents Chemother 45 2001 170-175
51. Aubier M. Verster R. Regamey C. Geslin P. Vercken J.B. Once daily sparfloxacin versus high dose amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults Clin Infect Dis 26 1998 1312-1320
52. Hernandez J.M. Sides G.D. Conforti P.M. Smietana M.G. Clinical efficacy of dirithromycin in patients with bacteremic pneumonia Clin Ther 18 1996 1128-1138